Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data
0:00 · Watch on YouTube
Moderna’s cancer-vaccine update disappointed the tape mainly because Wall Street’s bar was already high after a run that left the stock near a $100 billion valuation, while healthcare specialist Jared Holes treats the...